McFlusion

The McFlusion Group – Experts in Cleaning & Sterilization Solutions

[McFlusion @McFlusion]

FDA rejects Hengrui, Elevar’s PD-1 liver cancer combo for a 3rd time https://t.co/Qbo2sQDKsA

[McFlusion @McFlusion]

Bausch + Lomb pivots asset to geographic atrophy after mid-stage glaucoma miss https://t.co/e6HWBP6eOr via @fwpharma

[Reuters Health @Reuters_Health]

China will add a second GLP-1 drug, used to treat diabetes, to a list of essential drugs all public hospitals are required to prioritise having in their formulary, a government statement said on Thursday. https://t.co/bVbivOig6G https://t.co/bVbivOig6G

[BioSpace @biospace]

Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.

https://t.co/5B1akEsnK8

[McFlusion @McFlusion]

Biopharma bites: AstraZeneca prevails on Tagrisso, Dr Reddy's semaglutide supply hitch, and Lundbeck's Vyepti warning https://t.co/u4Bwdk8Ek3 via @fwpharma

[Reuters Health @Reuters_Health]

Indian drugmaker Dr Reddy's Laboratories said on Thursday it will delay supplies of its generic diabetes drug due to an issue with the active pharmaceutical ingredient, erasing $678 million from its market capitalisation. https://t.co/Oml7gPDuhj https://t.co/Oml7gPDuhj

[McFlusion @McFlusion]

ARPA-H launches $160 million effort to develop custom gene editing drugs https://t.co/ZyYIFRkK09 via @statnews

[McFlusion @McFlusion]

Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report https://t.co/7VJ7zJlz2b

[McFlusion @McFlusion]

Vera moves into growing kidney disease space with FDA’s accelerated IgAN nod https://t.co/7udux0IkZT

[McFlusion @McFlusion]

GSK cuts losses on $700M upfront Alzheimer’s collab with Alector following 2 clinical failures https://t.co/KrJDTGEgff

[McFlusion @McFlusion]

https://t.co/UzpcufWzTj

[US FDA MedWatch @FDAMedWatch]

Early Alert: Convenience Kits Issue from Medline https://t.co/Q4nTShvgBU

[McFlusion @McFlusion]

Cancer, rare disease dominate FDA approvals in H1 2026 as AstraZeneca, J&J clean up https://t.co/HmpH46f4BP

[McFlusion @McFlusion]

AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3 https://t.co/hA5in8TlIL

[McFlusion @McFlusion]

BMS’ Krazati kneels to chemo in confirmatory colorectal cancer trial https://t.co/hbv551DojD

[Pharmaceutical Market Europe @PMLiVEcom]

Teva submits FDA application for paediatric Tourette syndrome therapy https://t.co/fztYl9sBs8

[FiercePharma @FiercePharma]

Vera’s new FDA nod portends an IgAN showdown with a pair of pharma heavyweights
https://t.co/92IopFM34a

[McFlusion @McFlusion]

FDA halts release of new drug rejection letters while working to formalize policy https://t.co/LujkgT16O2

[BioSpace @biospace]

A mostly black box since emerging with more than a billion dollars in hand, Xaira Therapeutics is slowly pulling back the curtain, revealing plans to find partners and validate its pipeline.

https://t.co/jR1owYs6Jn

[McFlusion @McFlusion]

Prime wins patent fight with Beam to continue work on AATD gene editing therapy https://t.co/stB2TAhLxb

[McFlusion @McFlusion]

Sanofi promises to play nice as EU probe looks into flu vaccine campaign https://t.co/yM22ZOcbzx via @fwpharma